Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)
Clinical trial NCT00443053 · COMPLETED
Trial details
- NCT number
- NCT00443053
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2007-03-01
- Primary completion
- 2009-07-01
- Enrollment
- 3002
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.